• Aucun résultat trouvé

Light-adjustable lens complication

N/A
N/A
Protected

Academic year: 2022

Partager "Light-adjustable lens complication"

Copied!
5
0
0

Texte intégral

(1)

Article

Reference

Light-adjustable lens complication

HAFEZI, Farhad, SEILER, Theo, ISELI, Hans Peter

HAFEZI, Farhad, SEILER, Theo, ISELI, Hans Peter. Light-adjustable lens complication. Der Ophthalmologe , 2010, vol. 117, no. 4, p. 848-848.e1

DOI : 10.1016/j.ophtha.2009.12.019 PMID : 20346825

Available at:

http://archive-ouverte.unige.ch/unige:22460

Disclaimer: layout of this document may differ from the published version.

1 / 1

(2)

with a Light-Adjustable Lens

Arturo Chayet, MD,

1

Chris Sandstedt, PhD,

2

Shiao Chang, PhD,

2

Paul Rhee, OD,

3

Barbara Tsuchiyama, BS,

2

Robert Grubbs, PhD,

4

Dan Schwartz, MD

5

Purpose:

To determine whether residual myopia could be corrected postoperatively using the light-adjustable lens (LAL) technology in patients undergoing cataract surgery and LAL implantation.

Design:

A prospective clinical study was conducted at Codet Vision Institute in Tijuana, Mexico. The LALs were implanted that would purposely result in myopic errors of up to

1.5 D (diopter). The LAL was treated with a spatial intensity profile delivered by a digital light delivery device to induce a targeted myopic refractive change.

Once the desirable myopic correction was achieved, the LAL was treated again to lock-in the lens power.

Participants:

Fourteen eyes of 14 patients were studied.

Methods:

The manifest refraction, uncorrected visual acuity (UCVA), and best- or spectacle-corrected visual acuity (BCVA), were measured with follow up time of 1 to 9 months to determine the achieved refractive corrections and their stability.

Main Outcome Measures:

We measured UCVA and BCVA, achieved versus targeted refractive outcome, and refractive stability with follow up time of 1 to 9 months.

Results:

Of 14 eyes, 13 eyes (92.9%) achieved 0.25 D of the target refraction at 1 day post lock-in with 100%

of the eyes achieving the targeted refractive adjustment within 0.5 D or better with up to 9 months postoperative follow-up. All eyes treated show no change in manifest spherical refraction

0.25 D between 1 day post lock-in, and 3, 6, and 9 months postoperative visits. The data demonstrate the stability of the achieved refractive change after the adjustment and lock-in procedures. The mean rate of change was 0.006 D per month, which is 6 times more stable than that of laser corneal refractive procedures.

Conclusions:

Residual myopia errors up to

1.5 D were successfully corrected with precision and signifi- cant improvement in UCVA and without compromising BCVA using the LAL technology.

Financial Disclosure(s):

Proprietary or commercial disclosure may be found after the references.

Ophthalmology 2009;116:1432–1435 © 2009 by the American Academy of Ophthalmology.

Biometric errors and wound healing introduce varying lev- els of imprecision into spherical refractive outcomes after cataract surgery. Although residual myopia after cataract surgery is preferable to hyperopia, it still limits uncorrected visual acuity (UCVA). This effect is most pronounced in patients undergoing surgery with intraocular lenses (IOLs) designed to treat presbyopia who wish to optimize UCVA at both near and distance. In a recent study of the Crystalens (Eyeonics, Inc, Aliso Viejo, CA), 60% of patients had UCVA of 20/20 if final refractive error was within 0.5 diopters of plano, whereas only 6.8% saw as well, if residual myopia was

0.5 diopters (manifest refraction spherical equivalent).

1

However, intentional residual myopia is used to provide monovision after cataract surgery. In this case, refractive precision is equally important to maximize near visual acuity. If undesired levels of myopia occur after cataract surgery, postoperative adjustment of IOL power is not possible with conventional IOLs, and patients some- times require additional corneal refractive surgery to opti- mize refractive outcomes. A light-adjustable lens (LAL) has been recently described, which enables noninvasive correc- tion of residual refractive error.

2– 4

The LAL contains photosensitive silicone macromers dispersed within the ultraviolet (UV)-absorbing silicone

lens matrix that enable postoperative, noninvasive adjust- ment of refractive power using UV light. The LAL formu- lation has been described previously

2

and is based on the principles of photochemistry and diffusion. The application of the appropriate wavelength of light through a defined spatial irradiance profile onto the LAL polymerizes the macromer in the exposed region, thereby producing a dif- ference in the chemical potential between the irradiated and nonirradiated regions. To reestablish thermodynamic equi- librium, macromers from the unirradiated portion of the lens diffuse along the concentration gradient into the photopo- lymerized portion of the lens, producing a change in shape and concomitant predictable power change.

By controlling the irradiation dose (i.e., beam irradiance and duration) and spatial irradiance profile, the refractive power of the LAL is modified to add or subtract spherical power, eliminate astigmatic error, and correct higher order aberrations. One day after LAL adjustment, the entire lens is irradiated to polymerize remaining photosensitive macro- mer and prevent additional change in lens power. This second irradiation procedure is referred to as “lock-in.”

To determine whether residual myopic refractive error

could be corrected postoperatively using the LAL, we per-

formed a pilot study in patients undergoing cataract surgery

(3)

with LAL implantation. Based on preoperative biometry, LALs were implanted that would purposely result in myopic refractive errors of up to

1.5 diopters. In this fashion, we were able to adjust lens power and test whether myopic refractive error could be corrected in the postoperative period. We intentionally targeted a myopic refractive out- come because extensive preclinical data (in vitro and in vivo in an animal model) confirmed the ability to adjust postop- erative myopic refractive errors precisely. Furthermore, if we had targeted patients for emmetropia, then large num- bers of patients would have to be enrolled to detect those with substantial postoperative refractive errors. This would expose excessive numbers of subjects to an investigational device.

Methods

The clinical study was initiated after Institutional Review Board approval at Codet Vision Institute under the direction of Dr Arturo Chayet. Subjects who required cataract extraction and IOL implan- tation and volunteered for this study were screened for eligibility.

Informed consent was signed by individually eligible patients.

Preoperative biometry was performed using an immersion biom- etry unit (Axis II Ophthalmic Echograph, Quantel Medical, Boze- man, MT) and LAL power was selected to result in a postoperative refractive error of up to ⫺1.5 diopters of myopia. All patients underwent phacoemulsification using a topical anesthetic, clear corneal incision (3.0 –3.5 mm) and anterior capsulorhexis. The LAL of the appropriate power was implanted in the capsular bag using the Nichamin II Foldable Lens Insertion Forceps. No suture was used to close the incision. The operative eye was patched after surgery as our standard of practice. The patch was removed the following day, and patients were instructed to wear Calhoun Vi- sion supplied UV-blocking photochromic spectacles at all times when indoors and outdoors until the adjustment and lock-in pro- cedures were completed.

The LAL was adjusted and locked in using a digital light delivery (DLD) system engineered by Carl Zeiss-Meditec (Jena, Germany). The DLD uses a mercury (Hg) arc lamp with a narrow bandpass interference filter producing a beam at 365 nm (⫾4 nm full width half maximum). The DLD generates and projects a spatial irradiance pattern onto the LAL using a digital mirror device. The digital mirror device is a pixilated, micromechanical spatial light modulator formed monolithically on a silicon sub- strate. The surgeon centers and focuses the treatment beam on the LAL using an alignment reticle while patient alignment is achieved using a fixation target parcentral to the delivery beam.

At 10 days to 3 weeks post-implantation, visual acuity (BCVA and UCVA) and residual myopic refractive error were measured.

The DLD was then used to adjust LAL power to correct the myopic error. Refractive power adjustments are defined at the spectacle plane. No attempt was made to correct coexisting astig- matism. This adjustment time frame was selected because refrac-

tive power after implantation has substantially stabilized. Data reported in literature revealed that⬎80% of the refractive power change owing to anterior chamber depth shift for 3-piece IOLs as a result of wound healing occurred at 1 day to 1 week postoper- atively.5– 8A second irradiation treatment was given a minimum of 20 hours after adjustment to lock-in the lens. The following study endpoints were evaluated:

Attempted versus achieved lens power change (manifest refraction).

Stability of adjusted lens power (manifest refraction).

Visual acuity (UCVA and BCVA).

Complications and adverse events.

Results

A total of 14 patients were treated for refractive adjustments in the range of 0.0 to⫺1.50 D and followed for 1 to 9 months postop- eratively. Of the 14 patients included in this study, 11 were male and 3 were female. The patients ranged in age from 46 to 83 years old with a mean of 67 years. All eyes were accounted for at the 1-, 3-, 6-, and 9-month postoperative visits inTable 1. There were no missed visits or any patients lost to follow-up during the study period. The distribution of refractive adjustments attempted can be found inTable 2.

Target versus Achieved Myopic Corrections

The accuracy of the achieved sphere to the targeted refractive adjustment is demonstrated in the bar graph presented inFigure 1

Figure 1. Target versus achieved myopic corrections bar graph. Of 14 eyes, 13 (93%) achieved⫾0.25 diopters of the targeted refractive adjust- ment in the range of 0.0 to⫺1.5 diopters. The remaining 1 eye was within 0.50 diopter of the targeted refraction., Targeted;e, achieved.

Table 1. Number of Patients and Postoperative Follow-up Time

No. of Patients (Total14) Postoperative Time (mos)

2 1

5 3

5 6

2 9

Table 2. Distribution of Refractive Adjustments Attempted

Attempted Sphere, Diopters n N %

⫺1.25 to⫺1.5 4 14 28.6

⫺0.75 to⫺1.0 5 14 35.7

⫺0.25 to⫺0.5 1 14 7.1

0 4 14 28.6

Total 14 14 100.0

n⫽number of eyes at each attempted sphere; N⫽total number of eyes.

Chayet et al

Myopia Correction with Light-Adjustable Lens

1433

(4)

and data inTable 3. Thirteen of the 14 eyes (92.9%) treated were within 0.25 D of the target refraction at 1 day after the lock-in visit with 100% of the eyes achieving 0.50 D of the targeted refractive adjustment at 1 day after lock-in, and at the 3-, 6-, and 9-month postoperative visits.

Stability of Refractive Adjustment

All 14 eyes (100%) were stable within 0.25 D with 13 eyes showing no change at a period up to 9 months postoperatively as compared with refraction at 1 day after lock-in treatment (Table 4).

The mean rate of change was 0.006 D per month, which is approximately 6 times more stable than that of laser corneal refractive procedures (0.04 D/month).9 These data demonstrate stability of the achieved refractive change after lock-in.

Uncorrected Visual Acuity

All 14 eyes demonstrated stability of UCVA after lock-in. The UCVA bar graph before and after the myopic corrections can be found inFigure 2. Ten of the 14 eyes achieved UCVA of 20/25 or better. All eyes achieved UCVA of 20/30 or better except one. In this 1 eye, UCVA improved from 20/100 before adjustment to 20/50 after adjustment. This eye was noted to have posterior capsular opacification immediately after the surgery. The BCVA of this eye was 20/40. Significant improvement in UCVA was observed in 71% (10/14) of eyes and UCVA was stable for a follow-up period up to 9 months.

Best-Corrected Visual Acuity

The BCVA before and after refractive adjustments are displayed in Figure 3. All 14 eyes were stable after refractive adjustment and lock-in treatments with a follow-up period of 9 months. The BCVA before and after refractive adjustments and lock-in were maintained at 20/25 for all patients throughout the follow-up period except one. This eye was noted to have posterior capsular opacification immediately after surgery. The BCVA was main- tained at 20/40 with a 3-month follow-up period.

Complications

There were no adverse events or complications detected.

Discussion

In a pilot study correcting for 0.0 to

1.5 diopters of myopia in the LAL, we demonstrate that 13 of 14 (93%) adjustments were within 0.25 diopters of the intended re- fraction and the remaining eye was within 0.5 diopters.

More than 70% of eyes had improved UCVA, and BCVA was maintained at 20/25 or better throughout a follow-up period up to 9 months except 1 patient (posterior capsular opacification noted after surgery). Although this study was limited to correction of up to 1.5 diopters, we have corrected

2.0 diopters of myopia in vitro. Further in vitro studies demonstrate the ability to correct up to 3.5 diopters of myopia with 2 adjustments separated by

24 hours (Cal- houn Vision, Inc, unpublished data, July 2004).

The ability to adjust LAL power precisely in patients with postoperative myopia has several applications. First, as demonstrated in this study, adjustment could be used to improve UCVA. Second, if a patient desired to be left with some degree of myopia for uncorrected intermediate or near acuity initially, but found monovision not tolerable later, the LAL could be adjusted and corrected for emmetropia. Un- like patients undergoing corneal refractive surgery to create

Table 3. Accuracy of Sphere to Target Myopic Corrections

Manifest Refraction Spherical Equivalence

1 Day After Lock-in

3 Months Postoperatively

6 Months Postoperatively

9 Months Postoperatively

n/N % n/N % n/N % n/N %

Within 0.25 D of attempted (%) 13/14 92.9 11/12 91.7 7/7 100.0 2/2 100.0 Within 0.50 D of attempted (%) 14/14 100.0 12/12 100.0 7/7 100.0 2/2 100.0 Within 1.0 D of attempted (%) 14/14 100.0 12/12 100.0 7/7 100.0 2/2 100.0 D⫽diopters; n⫽number of eyes at each attempted sphere; N⫽total number of eyes.

Table 4. Stability of Refractive Adjustment

Change of Refraction (diopters)

No. of Eyes (N14)

Follow-up Time (mos)

0 13 1–9

0.25 1 1–3

Figure 2. Bar graph of uncorrected visual acuity (UCVA) before and after myopic corrections (20/20⫽1.0; 20/40⫽0.5; 20/100⫽0.2). Significant improvement in UCVA was observed in 71% of eyes. Of 14 eyes, 10 (71%) eyes achieved UCVA ofⱖ20/25. All eyes wereⱖ20/30 and stable for a follow-up period up to 9 months except one. Posterior capsular opacification was noted on the 1 eye immediately after surgery., Before;

e, after.

(5)

monovision who can be tested preoperatively with a contact lens trial, it is difficult to determine monovision tolerance in patients with cataracts because of media opacity. Some patients do not tolerate monovision owing to reduced contrast sensitivity and stereoacuity, as well as esophoric shifts.

10,11

During the time that the patient implanted with an LAL acclimated to monovision, he or she would have to wear protective UV glasses so the lens would not develop undesired optical changes from outside ambient light exposure.

Although we demonstrated the potential to reverse mod- erate myopia in the postoperative period, optimal UCVA can only be obtained by correcting astigmatic error as well.

We are currently refining nomograms for correction of toric refractive error.

References

1. Cumming JS, Colvard DM, Dell SJ, et al. Clinical evaluation of the Crystalens AT-45 accommodating intraocular lens:

results of the U.S. Food and Drug Administration clinical trial.

J Cataract Refract Surg 2006;32:812–25.

2. Schwartz DM. Light-adjustable lens. Trans Am Ophthalmol Soc 2003;101:417–36.

3. Schwartz DM, Sandstedt CA, Chang SH, et al. Light-adjustable lens: development of in vitro nomograms. Trans Am Ophthalmol Soc 2004;102:67–72.

4. Sandstedt CA, Chang SH, Grubbs RH, Schwartz DM. Light- adjustable lens: customizing correction for multifocality and higher-order aberrations. Trans Am Ophthalmol Soc 2006;

104:29 –39.

5. Koeppl C, Findl O, Kriechbaum K, et al. Postoperative change in effective lens position of a 3-piece acrylic intraocular lens.

J Cataract Refract Surg 2003;29:1974 –9.

6. Wirtitsch MG, Findl O, Menapace R, et al. Effect of haptic design on change in axial lens position after cataract surgery.

J Cataract Refract Surg 2004;30:45–51.

7. Sugar A, Sadri E, Dawson DG, Musch DC. Refractive stabi- lization after temporal phacoemulsification with foldable acrylic intraocular lens implantation. J Cataract Refract Surg 2001;27:1741–5.

8. Nejima R, Miyai T, Kataoka Y, et al. Prospective intrapatient comparison of a 6.0-millimeter optic single-piece and 3-piece hydrophobic acrylic foldable intraocular lenses. Ophthalmol- ogy 2006;113:585–90.

9. Vision Council. Standard for Laser Systems for Corneal Reshap- ing. ANSI Z80.11-2007. Fairfax, VA: Optical Laboratories Association; American National Standards Institute; 2007:38.

10. Erickson P, McGill EC. Role of visual acuity, stereoacuity, and ocular dominance in monovision patient success. Optom Vis Sci 1992;69:761– 4.

11. Jain S, Arora I, Azar DT. Success of monovision in presbyopes:

review of the literature and potential applications to refractive surgery. Surv Ophthalmol 1996;40:491–9.

Footnotes and Financial Disclosures

Originally received: May 30, 2008.

Final revision: January 14, 2009.

Accepted: February 11, 2009.

Available online: June 4, 2009. Manuscript no.: 2008-663.

1Codet Vision Institute, Tijuana, Mexico.

2Calhoun Vision, Inc., Pasadena, California.

3Lake Forest, California.

4California Institute of Technology, Pasadena, California.

5University of California at San Francisco, San Francisco, California.

Financial Disclosure(s):

The authors (CS, SC, BT) are Calhoun Vision employees. PR is a former Calhoun Vision employee. AC is the clinical investigator for Calhoun Vision, compensated only for his typical surgery fee for each patient, with no financial interest. DS and RG are both Founding Scientists and a Board Member of Calhoun Vision with financial interest.

Supported by SBIR grant EY12181-02.

Correspondence:

Arturo Chayet, MD, Ave. Padre Kino No. 10159, Tijuana, Mexico 22320.

E-mail:arturo.chayet@codetvision.com.

Figure 3. Bar graph of best-corrected visual acuity (BCVA) before and after myopic corrections (20/20⫽1.0; 20/40⫽0.5; 20/100⫽0.2). All eyes were stable and able to maintain their preadjustment BCVA., Before;e, after.

Chayet et al

Myopia Correction with Light-Adjustable Lens

1435

Références

Documents relatifs

With regard to ophthalmological complications, we specifically detailed the severity of visual acuity loss defined by a visual acuity without scleral lens of ≤20/200 in the worst

microneurography, we recorded the unitary activity of muscle spindle afferents in healthy subjects during passive movements of the foot, while they listened to evocative

muscle spindles relating to the ankle joint and participants’ emotional state was manipulated through listening to evocative classical music, to induce sad, neutral, or

In Experiment 2, we looked for evidence of parafoveal-on-foveal effects—whether properties of the parafoveal noun (Word 2, the second word of the noun phrase) affected measures

For eligible patients, the following data were collected from their medical charts: demographic data (i.e., age, sex); dura- tion of diabetes; stage of diabetic

b Mean central retinal thickness (CRT) curve in micrometers of mean values for the central subfield on optical coherence tomography measurement for all included patients treated

Normalization explains interplay of contrast and acuity While providing a mechanistic explanation for the loss of visual acuity in TrkB.T1-EGFP mice, these results did not explain

Abstract: The purpose of this study is to evaluate the visual acuity (VA) gain profiles between patients with drug-naive diabetic macular edema (DME) treated by dexamethasone